Passage Bio Inc. held its 2025 Annual Meeting of Stockholders on May 28, 2025. During the meeting, two Class II directors, Maxine Gowen, Ph.D., and Dolan Sondhi, Ph.D., were elected. Additionally, the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. The stockholders also approved a proposal allowing the Board of Directors to implement a reverse stock split of the company's outstanding shares of common stock at a ratio between 1-for-5 and 1-for-50, with the exact ratio to be determined by the Board prior to December 31, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.